ARCHIVES

ODAC Recommends Fludarabine Approval for Refractory CLL

This article is from The Cancer Letter archive.

Vol. 16 No. 36 | September 21, 1990

Download PDF Visit The Full Archive

Related Articles

Cancer Program Should Get $2 Billion A Year, Amos Says; “Feds Short On Money, Long of Regs”: Yarbro

March 25, 1983

L-PAM Benefit To Post-Menopausal Patients Challenged

October 29, 1976

FDA Needs Staff, Funds But first Must Determine Priorities, GAO Says

November 17, 1989

NCI Community Cancer Centers RFP Issued; Advisors Criticize Project Structure.

November 10, 2006

DCPC Advisors Approve Five New RFA concepts, Set Aside $33.6 Million

June 4, 1993

Turmoil in Texas: SEC Issues Subpoena to AVEO on Tivozanib

July 12, 2013